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Brucellosis is a zoonosis of nearly worldwide distribution. Vaccination against this pathogen is an important
control strategy to prevent the disease. Currently licensed vaccine strains used in animals are unacceptable for
human use due to undesirable side effects and modest protection. Substantial progress has been made during
the past 10 years toward the development of improved vaccines for brucellosis. In part, this has been achieved
by the identification and characterization of live attenuated mutants that are safer in the host but still can
stimulate an adequate immune response. In the present study, the identification and characterization of the
mucRmutant (BMEI 1364) as a vaccine candidate for brucellosis was conducted. BALB/c mice were vaccinated
intraperitoneally at a dose of 105 CFU with the mutant to evaluate safety and protective efficacy against
intraperitoneal and aerosol challenge. All animals vaccinated with the vaccine candidate demonstrated a
statistically significant degree of protection against both intraperitoneal and aerosol challenge. Safety was
revealed by the absence of Brucella associated pathological changes, including splenomegaly, hepatomegaly, or
granulomatous disease. These results suggest that the 16MmucR vaccine is safe, elicits a strong protective
immunity, and should be considered as a promising vaccine candidate for human use.
Brucella spp. are a diverse group of pathogens causing dis-
ease in many hosts, including humans. As the cause of brucel-
losis, Brucella abortus and B. melitensis are of particular impor-
tance to human health, with an estimated annual incidence of
500,000 human cases worldwide but predominantly in devel-
oping countries (31). Vaccination against brucellosis is an im-
portant control strategy to prevent the disease (29). Currently
licensed vaccine strains implemented in the veterinary field are
unacceptable for human use due to the undesirable side ef-
fects, antibiotic resistance, and lack of characterization (33,
37). Increased knowledge of protective immune responses to
Brucella infection, along with the elucidation of the com-
plete genomic sequence have provided better opportunities
to understand, develop, and improve new vaccines against
brucellosis.
Previous studies performed in this laboratory using signa-
ture-tagged mutagenesis permitted the identification of in vitro
and in vivo virulence genes (1, 16, 40). Among these, a mucR
(BMEI 1364) mutant was attenuated for survival in the mouse
and macrophage model (40). The role of MucR protein in
Brucella is unknown, but the function of the mucR gene has
recently been identified in soil and plant bacteria such as Agro-
bacterium tumefaciencis and Sinorhizobium meliloti (19, 28).
MucR is a transcriptional regulator that coordinates a diverse
set of bacterial behaviors, including the control of exopolysac-
charide production, which is important not only in bacterium-
plant symbiosis but also in biofilm formation (4, 5).
In the present study, we conducted a series of experiments
designed to characterize B. melitensis 16MmucR as a poten-
tial candidate vaccine against intraperitoneal and aerosol B.
melitensis 16M challenge. Vaccination with the mutant did not
induce systemic or local adverse reactions and significantly
protected BALB/c mice against intraperitoneal and aerosol
challenge.
MATERIALS AND METHODS
Mice. Six- to eight-week-old female BALB/c mice were obtained from the
Jackson Laboratories (Bar Harbor, ME) and acclimated for 1 week prior to
infection or vaccination. All experimental procedures and animal care were
performed in compliance with the institutional animal care guidelines.
Bacterial strains. Strains used in these experiments include B. melitensis
16MmucR (engineered for the present study and used as the vaccine candidate)
and the virulent strain B. melitensis16M biovar 1(originally obtained from the
American Type Culture Collection and reisolated by this lab from an aborted
goat fetus) (24). Bacteria were grown on tryptic soy agar (TSA; Difco/Becton
Dickinson) or Farrell’s medium (TSA supplemented with Oxoid Brucella sup-
plement) at 37°C with 5% CO2. For construction of the B. melitensis 16MmucR
knockout, the medium was supplemented with kanamycin (100 g/ml) or car-
benicillin (100 g/ml). Sucrose medium was utilized for sacB counterselection
and unmarked gene deletion selection as previously described (25). Escherichia
coli cultures utilized for the construction of the 16MmucR mutant were grown
on Luria-Bertani (LB) (Difco/Becton Dickinson) plates or in LB broth overnight
at 37°C with or without ampicillin (100 mg/liter) or kanamycin (100 mg/liter).
To prepare organism for animal infections, Brucella were harvested from the
surface of the plates after 3 days of incubation using phosphate-buffered saline
(PBS; pH 7.2). The bacteria were pelleted and resuspended to a final concen-
tration based on optical density readings using a Klett meter and a standardized
curve. Actual viable counts were confirmed by serial dilution, plating, and enu-
meration.
Construction of the B. melitensis 16MmucR deletion mutant. The mutant was
constructed as previously described with some modifications (25). The sequence
upstream of the mucR gene (BMEI1364) was amplified from B. melitensis 16M
by using the primer pair 5-GCTCTAGAGCCCATCAACAACAGGACAAAC
GG-3 (contains an XbaI site) and 5-GGCGGCGCGCCTGGTTGCTCCGAA
CTATGCTG (contains an AscI site). The sequence downstream of mucR was
amplified with the primer pair 5-CCAGGCGCGCCGCCGCTGCGTATTTCA
TAATC (contains an AscI site) and 5-GCTCTAGAGCCTTTGCAGGTTTTC
CGTATCTTT (contains an XbaI site). These two products were ligated to one
another via overlapping PCR via the AscI site (New England Biolabs) engi-
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neered between the two sequences. This overlap product was then ligated to
pEX18Ap via the XbaI site (named pMMK40). A kanamycin resistance (Kanr)
gene was subsequently ligated within the vector by the unique AscI site (plasmid
pMMK44). This construct was used for electroporation into Brucella melitensis
16M. Potential marked deletion mutants were Kanr and carbenicillin sensitive
(Carbs) and were verified by PCR and Southern blotting; the confirmed mutant
was named 16MmucR::Kan. The unmarked deletion mutant was engineered by
electroporation of pMMK40 into 16MmucR::Kan and selected on TSA plus
carbenicillin at 100 g/ml. Cointegrants with the phenotypes Kanr, Carbr, and
sucrose sensitive (Sucs) were selected, indicating a cointegrant with a functional
sacB gene. Bacteria were selected in the presence of sucrose for resolution of
cointegration as previously described (25). All knockout candidates were verified
by PCR and Southern blotting to demonstrate gene deletion and loss of the Kan
cassette.
Evaluation of B. melitensis 16MmucR attenuation in mice. Forty 6- to 8-week-
old female BALB/c mice were used to evaluate the persistence and replication of
the B. melitensis 16MmucR mutant. Mice were inoculated intraperitoneally with
either (i) 106 CFU in 100 l of 16MmucR or (ii) 106 CFU in 100 l of the
parental strain 16M. Groups of four mice were euthanized via carbon dioxide
asphyxiation at 1, 3, 6, 9, or 12 weeks postinfection. At each time point, the
spleens were harvested, weighed, and homogenized in 1 ml of peptone saline.
Serial dilutions were prepared, and 100-l aliquots of each dilution (including
the undiluted organ) were plated in duplicate onto TSA plates. The levels of
infection were expressed as means  the standard errors of the mean (SEM) of
individual log CFU/spleen values.
Immunization of mice for efficacy studies. Six- to eight-week-old female
BALB/c mice were distributed into three treatment groups and inoculated in-
traperitoneally with a single dose of B. melitensis 16MmucR. Treatment groups
included doses of 105 CFU/mouse, 106 CFU/mouse, and PBS only as a control.
Mice were housed for 20 weeks postvaccination under ABSL-3 conditions.
Vaccination efficacy against intraperitoneal challenge. At 20 weeks postvac-
cination, mice (n  5 per group) were challenged intraperitoneally using 6  105
CFU of B. melitensis 16M/mouse. At 1 week postchallenge, the mice were
euthanized via CO2 asphyxiation. Spleens, lungs, and livers were collected,
weighed, and homogenized in 1 ml of PBS and plated onto TSA or Farrell’s
medium plates to determine the total CFU/organ. Serial dilutions were per-
formed, and aliquots were plated. The levels of infection were expressed as
means the SEM of the individual log10 CFU/spleen, log10 CFU/liver, and log10
CFU/lung values.
Vaccination efficacy against aerosol challenge. At 20 weeks postvaccination,
groups of five mice were challenged with an aerosol chamber dose of 5  109
CFU of B. melitensis 16M/ml. At 4 weeks postchallenge, the mice were eutha-
nized, and the lungs, livers, and spleens were removed, weighed, homogenized in
1 ml of PBS, serially diluted, and plated onto Farrell’s medium to determine total
CFU/organ. The levels of infection were expressed as means  the SEM of the
individual log 10 CFU/spleen, log10 CFU/liver, and log10 CFU/lung values. A
group of three mice were euthanized directly after aerosol exposure to quantify
the CFU/lung inhaled.
Histopathology. Tissues from mice were assessed to determine the degree of
pathology associated with aerosol challenge. Mice were either vaccinated with
16MmucR and subsequently aerosol challenged (2 weeks postchallenge) or not
vaccinated (i.e., naive) and aerosol challenged (2 weeks postchallenge). The
animals were euthanized by CO2 asphyxiation, and the spleens, lungs, livers,
kidneys, and hearts were harvested, fixed in 10% buffered formalin, paraffin
embedded, and stained with hematoxylin and eosin. The histological changes
were assessed between groups. Slides were analyzed by a board-certified veter-
inary pathologist.
Statistical analysis. Bacterial burden from mutant clearance and efficacy stud-
ies are expressed as the mean CFU the standard errors (SE) and are presented
graphically as the log10 CFU of Brucella recovered per organ. Culture-negative
organs were assigned a value of 4 CFU, which is below the limit of detection of
5 CFU/organ. Spleen weight data from kinetics studies are plotted as the mean
spleen weights in mg  the SE.
For the survival of 16MmucR in mice, a Student t test was performed to
compare splenic colonization and weight of the knockout strain to the wild-type
control group at each time point. Efficacy studies compared vaccinated and
subsequently challenged mice to mice receiving PBS as a vaccine control that
were challenged with the wild-type organism. In the intraperitoneal challenge
study, statistical significance of differences between vaccinates were analyzed by
analysis of variance (ANOVA) for each organ separately, followed by Tukey’s
honestly significant (HSD) post test comparing all groups to one another. In the
aerosol protection studies a Student t test was performed for each organ sepa-
rately to compare the vaccinees to naive mice. For all statistical analyses, P values
of 0.05 were considered statistically significant.
RESULTS
Attenuation of 16MmucR in mice. To determine the effect
of the mucR gene deletion in vivo, mice were infected intra-
peritoneally with 106 CFU of B. melitensis 16MmucR/mouse.
Compared to the wild-type strain 16M, the colonization of the
spleen with 16MmucR was significantly reduced at 1, 3, and 6
weeks (P  0.01) but not at 9 or 12 weeks (Fig. 1A). Reduced
splenic colonization by the 16MmucR mutant correlated with
reduced spleen weights (Fig. 1B), indicating a reduced inflam-
matory response by the mutant. The spleen weights of mice
infected with wild-type 16M were consistently higher.
FIG. 1. Kinetics of clearance of 16MmucR from mice. Forty 6- to
8-week-old female BALB/c mice were used to evaluate the persistence
and replication of 16MmucR. Mice were inoculated intraperitoneally
with either (i) 106 CFU in 100 l of 16MmucR or (ii) 106 CFU in 100
l of the parental strain 16M. Groups of four mice were euthanized via
carbon dioxide asphyxiation at 1, 3, 6, 9, or 12 weeks postinfection. At
each time point, the spleens were harvested, weighed, and homoge-
nized in 1 ml of peptone saline. Serial dilutions were prepared, and
100-l aliquots of each dilution (including the undiluted organ) were
plated in duplicate on TSA plates. (A) The levels of infection were
expressed as means  the SEM of individual log CFU/spleen values.
(B) The spleen weights were measured and used to compare the
mutant strain to the wild-type organism. Statistical significance is based
upon a Student t test comparing the deletion mutant to the wild-type
strain. The solid line at 0.69 logs represents the lower limit of detection
(5 CFU).
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Evaluation of immune protection provided by 16MmucR
against intraperitoneal 16M challenge. In order to determine
the vaccination efficacy elicited by the 16MmucR mutant, the
level of protection provided by the vaccine candidate was eval-
uated against intraperitoneal B. melitensis 16M wild-type chal-
lenge at 20 weeks postvaccination. Animals were euthanized at
1 week postchallenge because this time point corresponds to
the highest bacterial load in the spleen based on previous
studies (25). At 1 week postchallenge (21 weeks postvaccina-
tion), there was a statistically significant decrease in the
splenic, hepatic, and pulmonary bacterial loads from the mice
vaccinated with the 16MmucR mutant relative to those of the
naive mice regardless of the vaccination dose, with a 4.14- to
4.75-log reduction in bacterial burden in the spleen (P 
0.001), 3.24- to 3.34-log reduction in the liver (P  0.001), and
2.54- to 3.64-log reduction in the lungs (P  0.001) (Fig. 2).
Evaluation of immune protection provided by 16mucR
against aerosol 16M challenge. In order to determine the vac-
cination efficacy elicited by the 16MmucR mutant against a
natural route of exposure, the level of protection provided by
the vaccine candidate was evaluated against aerosol B. meliten-
sis 16M wild-type challenge at 20 weeks postvaccination. For
aerosol exposure studies, the 4-week postchallenge time point
was chosen as the time point of peak splenic colonization (23).
Mice that were euthanized within 1 h of aerosol exposure
inhaled an average of 2.1  104 CFU/lungs, as determined by
plating their lungs and enumerating the bacteria recovered.
When mice were challenged by the aerosol route, the
16MmucR vaccine candidate protected mice significantly in
all organs plated. The mutant afforded a 2.79-log reduction in
the bacterial burden in the spleen (P  0.05), a 1.97-log re-
duction in the liver (P  0.05), and a 1.63-log reduction in the
lungs (P  0.01) (Fig. 3).
Evaluation of histological changes in mice vaccinated with
16MmucR. Histological analysis of the lungs, livers, and
spleens of BALB/c mice inoculated with either 16MmucR
(Fig. 4D, E, and F) or naive PBS controls (Fig. 4A, B, and C)
that were subsequently aerosol challenged with wild-type 16M
and euthanized 2 weeks postchallenge was assessed to deter-
mine the degree of inflammation elicited by the challenge
organism in animals that were vaccinated with the mutant.
Histologically, the bronchiole-associated lymphoid tissue was
prominent at 2 weeks postchallenge (Fig. 4A), and no signifi-
cant changes were seen in mice vaccinated with the mucR
mutant (Fig. 4D). Inflammatory foci in the liver of naive aero-
sol challenged mice were rare at 2 weeks postchallenge (Fig.
4B) and absent in mice vaccinated with the mucR mutant (Fig.
4E). Changes in the spleen of naive mice consisted of marked
extramedullary hematopoiesis at 2 weeks postchallenge (Fig.
4C). There were no significant changes in the spleen of mice
vaccinated with the mucR mutant (Fig. 4F). No significant
changes were observed in the kidneys or hearts in vaccinated or
aerosol exposed animals (data not shown).
DISCUSSION
Historically, the most efficacious vaccines against brucellosis
have been live attenuated vaccines, as is the case for multiple
currently licensed vaccine strains for animal use, including S19,
Rev1, and RB51 (15, 37). Unfortunately, both S19 and Rev1
vaccines, which have been highly efficacious in controlling the
disease in cattle and goats, respectively, have proven to be
unsafe or have the capacity to cause adverse reactions in hu-
mans due to local and systemic reactions that in some cases
resulted in the development of the disease (3, 38). Other vac-
cinology alternatives, including the use of subunit, recombi-
nant proteins and DNA vaccines which might be safer for
human use, though capable of eliciting both humoral and cel-
lular immune responses to a certain degree, generally induce
lower or no protection compared to the live attenuated vac-
cines in animal models (8–10, 14, 30, 32, 33, 36). As such, a live
FIG. 2. Protection against homologous intraperitoneal 16M chal-
lenge. Groups of five female BALB/c mice were vaccinated with
16MmucR at either 106 CFU/mouse or 105 CFU/mouse or left un-
vaccinated as naive controls. At 20 weeks postvaccination all animals
were challenged with 6  105 CFU/mouse intraperitoneally. At 1 week
postchallenge, mice were euthanized via CO2 asphyxiation, and the
spleens, livers, and lungs were collected. The data are reported as the
log10 recovery of Brucella from organs. The solid line at 0.69 logs
represents the lower limit of detection (5 CFU). Statistical analysis
was performed by ANOVA for each organ separately, followed by a
Tukey’s HSD post test comparing all groups to one another.
FIG. 3. Protection against homologous aerosol 16M challenge.
Groups of five female BALB/c mice were vaccinated with 16MmucR
at 105 CFU/mouse or left unvaccinated as naive controls. At 20 weeks
postvaccination, all of the animals were challenged with an aerosol
chamber dose of 5  109 CFU of 16M/ml. At 4 weeks postchallenge,
the mice were euthanized via CO2 asphyxiation, and the spleens, livers,
and lungs were collected. The data are reported as the log10 recovery
of Brucella from organs. The solid line at 0.69 logs represents the lower
limit of detection (5 CFU). Statistical analysis was performed by
using a Student t test comparing vaccinated to nonvaccinated mice for
each organ separately.
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attenuated organism has been utilized as the vaccine type of
choice for the prevention of brucellosis. An ideal Brucella
vaccine would be one that persists long enough to generate a
robust immune response without eliciting the undesired side
effects such as splenomegaly or clinical signs of disease.
Previous investigations using signature-tagged mutagenesis
in this laboratory have identified multiple candidate mutants
that are attenuated for virulence and survival in the mouse and
macrophage models, among these is disruption of the mucR
locus in B. melitensis 16M (40). We previously demonstrated an
in vitro and in vivo role for the mucR transposon mutant. The
organism was found to be significantly attenuated for survival
in vitro and in vivo when the gene was interrupted. To further
characterize the role of mucR in regard to survival, protective
efficacy, and safety in vivo, an unmarked gene deletion was
created.
In the Gram-negative soil bacterium Sinorhizobium meliloti,
a clear role for the mucR gene has recently been established
(28). MucR has been identified as a transcriptional regulator
with multiple functions that help in the establishment of sym-
biosis, including a key role in the control of exopolysaccharide
biosynthesis, which is necessary for biofilm formation (4, 5, 35).
The biofilm provides bacteria with a physical barrier against
antibiotics, innate defense mechanisms from the host, and en-
vironmental stress conditions, including UV radiation, pH
changes, and osmotic shock among others (11, 12). In order to
ensure a successful symbiotic association, exopolysaccharide
production and biofilm formation are tightly regulated and
partially controlled by the mucR gene. Deletion of mucR in S.
meliloti therefore results in deficiencies in the invasion or the
establishment of symbiosis. Other established roles of mucR in
this organism include an induction of increased expression of
multiple operons required for nitrogen fixation and respira-
tion, as well as numerous type IV secretion systems and puta-
tive transport-related genes, all of which are necessary for a
successful symbiosis (28).
In the case of Brucella, the role of mucR is less well understood.
Preliminary studies from this laboratory using microarray tech-
nology suggests that the mucR gene regulates exopolysaccharide
biosynthesis, as well as genes involved in iron sequestration and
storage, nitrogen metabolism, and stress response mechanisms.
(J. Weeks, unpublished data). Although preliminary and still un-
der investigation, all of these putative roles of MucR in Brucella
explain to a certain degree the attenuation of the mutant strain
observed in J774A macrophages and in mice. Recently, it has
been reported that B. melitensis 16M produces an exopolysaccha-
ride; studies suggested that Brucella may indeed be capable of
biofilm formation (17). It is possible that MucR may play a role in
FIG. 4. Histological changes of organs associated with vaccination and challenge. BALB/c mice were vaccinated with 16MmucR at 105
CFU/mouse or left unvaccinated as naive controls. At 20 weeks postvaccination, all of the animals were challenged with an aerosol chamber dose
of 5  109 CFU of 16M/ml. At 2 weeks postchallenge, tissues were collected for histology. The histology of the nonvaccinated but challenged
animals (A, B, and C) were compared to vaccinated but challenged animals (D, E, and F). The lungs (A and D), livers (B and E), and spleens (C
and F) were compared to determine the reduction in pathology afforded by vaccination with the 16MmucR mutant. Naive mice are depicted (G,
H, and I) for comparison. Hematoxylin and eosin staining was used (10 magnification).
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biofilm formation through the regulation of exopolysaccharide
synthesis.
Protective efficacy as a function of persistence has been
previously evaluated by this laboratory (25). The construction
and characterization of multiple deletion mutants in Brucella
abortus and Brucella melitensis has led to the conclusion that a
vaccine candidate needs to persist in the host long enough in
order to mount a strong protective immune response (15, 25).
This observation is apparent here, as well with the B. melitensis
mucR mutant. Interestingly, the mucR mutant persists for at
least for 12 weeks in mice, similarly to the wild-type 16M, but
the degree of colonization is significantly reduced compared to
the parental strain during the acute phase of the infection. This
difference in colonization properties may explain the lack of
gross and microscopic changes associated with infection. Lack
of hepatic granuloma formation or splenomegaly associated
with vaccination suggests that immunization with the mutant is
safe and therefore superior to many other Brucella vaccines,
including licensed ones (12). Most importantly, protection
against the most common microscopic changes associated with
the disease in mice, such as granulomatous hepatitis, granulo-
matous splenitis, or splenomegaly, was not observed, indicating
that vaccination with the mucR mutant not only reduced the
bacterial burden in multiple organs but also prevents against
the development of Brucella-associated pathological changes.
Lack of splenomegaly associated with vaccination has been
previously demonstrated as a safety parameter in other Bru-
cella vaccine candidates (2).
Protection against intraperitoneal challenge, observing the
output of bacterial colonization in the spleen of mice, has been
historically used as a means of evaluating Brucella vaccine
efficacy (6, 27, 34, 39). Although this vaccination or challenge
location does not reflect a natural route of infection, it has
been extremely useful in determining the potential efficacy of
vaccine candidates against brucellosis. Most importantly, it
provides a reproducible and invariable means of comparing
multiple vaccine candidate strains that had been studied for
the past 30 to 50 years. When 16MmucR vaccinated mice
were challenged against wild-type B. melitensis 16M, all of the
animals demonstrated a statistically significant reduction in the
bacterial burden in the spleen, lung, and liver regardless of
the vaccination dose. The marked reduction in bacterial bur-
den in the spleen conferred by the mutant is impressive and
comparable to other live attenuated vaccine candidates tested
by this laboratory and others (2, 20, 21, 25). Although an
intraperitoneal challenge is of historical importance, a more
logical approach is the use of an aerosol challenge route, not
only because of the documented evidence of aerosol transmis-
sion of these organisms but also because of the potential threat
of the use of Brucella as a bioterrorism agent (13, 18, 22, 26).
It has been documented that 10 to 100 organisms are enough
to cause disease in humans, and Brucella is therefore consid-
ered highly infectious when delivered by this route (7). Previ-
ous investigations performed by this laboratory have deter-
mined that BALB/c mice receiving an infectious dose of 5 
109 CFU/ml added to the chamber nebulizer inhaled an aver-
age of 12,250 organisms per mouse (4.10 logs) and that tissue
colonization reached a peak by 4 weeks postexposure (23). The
high dose (100-fold more bacteria that actually needed to es-
tablish an infection) and the time postvaccination chosen to
test efficacy provide us the means to evaluate the vaccine can-
didate efficacy under the most stringent conditions. Interest-
ingly and importantly, the bacterial burdens in the spleen, liver,
and lungs were markedly reduced in animals that received the
vaccine, demonstrating the vaccine efficacy against an aerosol
exposure. Gross and microscopic evaluation confirmed the
protection against the pathological changes associated with the
disease. As expected, the highest numbers of bacteria were
isolated from the lung. It is possible that a diminished inflam-
matory response in the lungs masks the efficacy in reducing the
bacterial colonization and, although high bacterial counts were
observed, there were no significant gross or microscopic
changes associated with the infection apart from an increased
amount of bronchus-associated lymphoid tissue.
In the present study, the intraperitoneal vaccination with the
live attenuated vaccine candidate 16MmucR was able to
markedly enhance the bacterial clearance in the spleen, lungs,
and liver using two different challenge routes. Most impor-
tantly, vaccination conferred protection against Brucella-asso-
ciated pathological changes. Future studies to determine the
correlates of immune protection and the function of MucR are
under way.
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